en · de · es · fr · pt
selank-notes.peptides9002.com › Guide › Selank Origin And Chemical Identity — Questions and Answers

Selank Origin And Chemical Identity — Questions and Answers

By Editorial Desk · published 2026-06-18 · last reviewed 2026-07-05 · Guide

Everything below concerns TP-7. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-07-05. Where a claim depends on a specific study, the study is described rather than over-claimed.

Selank Origin and Chemical Identity

Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.

The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.

Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.

Peptide Identity and Structure

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.

The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.

Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.

Selank at a glance

PropertyValueNotes
Chemical classSynthetic heptapeptideAnalog of the tetrapeptide tuftsin
SequenceThr-Lys-Pro-Arg-Pro-Gly-ProReported consistently across pharmacopoeial descriptions
AppearanceWhite to off-white lyophilized powderTypical form of research-grade material
SolubilityFreely soluble in waterAqueous buffers; poor in nonpolar solvents
Typical storage temperature-20 degrees CelsiusLyophilized powder; protect from moisture

Identity and Structural Background

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.

Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.

Related pages on this site

Analytical Methods and Handling

Characterization of Selank in a laboratory setting relies on standard peptide methods. Reverse-phase high-performance liquid chromatography separates the target from related impurities and provides a purity figure, commonly reported as 95 percent or higher. Mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, confirms the molecular mass and helps detect truncation or modification. Amino acid analysis can verify composition when a sequence-level check is needed. These techniques together establish identity and purity for a given lot.

Lyophilized Selank, the dry powder form, is generally stored frozen at minus 20 degrees Celsius or colder for long-term keeping. The solid is hygroscopic and should stay sealed, dry, and protected from light. Once dissolved, the peptide is less stable and is usually held refrigerated at 2 to 8 degrees Celsius for short periods. Repeated freezing and thawing is avoided because it can promote aggregation and loss of activity. Buffers and pH choice also affect how long a solution remains usable.

Background from the literature

A 2004 meta-analysis of randomised controlled clinical trials that compared benzodiazepines to zopiclone or other Z drugs such as zolpidem and zaleplon has found few clear and consistent differences between zopiclone and the benzodiazepines in sleep onset latency, total sleep duration, number of awakenings, quality of sleep, adverse events, tolerance, rebound insomnia, and daytime alertness.

=== E1 subunit === E1 uses thiamine pyrophosphate (TPP) as a catalytic cofactor. E1 catalyzes both the decarboxylation of the α-ketoacid and the subsequent reductive acylation of the lipoyl moiety (another catalytic cofactor) that is covalently bound to E2.

=== Persona non grata === The government of a country can declare a diplomat persona non grata, banning them from entering the country or expelling them if they have already entered. In non-diplomatic use, the authorities of a country may also declare a foreigner persona non grata permanently or temporarily, usually because of unlawful activity.

Sources: en.wikipedia.org

Reference notes

In May 2002, The Bill & Melinda Gates Foundation purchased stock in Merck. From 2002 through 2005, the Australian affiliate of Merck paid publishing house Elsevier an undisclosed amount to produce eight issues of a medical journal, the Australasian Journal of Bone and Joint Medicine. Although it gave the appearance of being an independent peer-reviewed journal, without any indication that Merck had paid for it, the journal actually reprinted articles that originally appeared in other publications and that were favorable to Merck. The misleading publication came to light in 2009 during a personal injury lawsuit filed over Vioxx; 9 of 29 articles in the journal's second issue referred positively to Vioxx. The CEO of Elsevier's Health Sciences Division, Michael Hansen, admitted that the practice was "unacceptable". Elsevier initially said that it compiled reprinted articles and it did not consider such compilation a journal. It was later forced to retreat and apologize. In 2005, Gilmartin retired as CEO following Merck's voluntary worldwide withdrawal of Vioxx. Gilmartin's tenure was criticized as abandoning Vagelos' commitment to corporate social responsibility. Former president of manufacturing Richard Clark was named CEO and company president. In November 2009, Merck & Co. completed a merger with Schering-Plough in a US$41 billion deal. Although Merck & Co. was in reality acquiring Schering-Plough, the purchase was declared a "reverse merger", in which "Old" Merck & Co.

=== Protein-protein interactions === Phosphorylation of the cytosolic components of NADPH oxidase, a large membrane-bound, multi-protein enzyme present in phagocytic cells, plays an important role in the regulation of protein-protein interactions in the enzyme. Important in protein degradation. In the late 1990s, it was recognized that phosphorylation of some proteins causes them to be degraded by the ATP-dependent ubiquitin/proteasome pathway. These target proteins become substrates for particular E3 ubiquitin ligases only when they are phosphorylated.

The studies and plans for the TTC's proposed "desperately needed extension known as the Relief Line", had begun in the late 2010s. By early 2019, the planning for the Relief Line was "well underway and construction was scheduled to begin in 2020, with projected completion in 2029." In April 2019, Ford put the Relief Line project on hold in favour of the Ontario Line, which would use a different route with significant lengths of at-grade or elevated track. On September 25, 2024, Ford promised to build a traffic tunnel under the Highway 401 to relieve congestion, and campaigned on constructing the Bradford Bypass. On October 21, 2024, Ford tabled a bill, titled the Reducing Gridlock, Saving You Time Act, granting the province authority to remove bike lanes from several arterial roads in Toronto, as well as expedite the construction of Highway 413. The bill would also require municipalities to get provincial approval before replacing any automotive lanes with bike lanes. Toronto City Council formally opposed the plan, citing an estimated cost of $48 million to remove the bike lanes on Bloor, Avenue, and Yonge. On November 21, Ford's government made several amendments to the bill which the opposition claimed would protect the province from liability if a cyclist were injured or killed due to the removal of the lanes. The bill passed on November 25, 2024. Ford's bill has faced opposition from local politicians and cycling advocates on grounds of provincial overreach and potential safety impacts to cyclists.

Sources: en.wikipedia.org

Notes from published material

Religion and alcohol have a complex history. The world's religions have had different relationships with alcohol, reflecting diverse cultural, social, and religious practices across different traditions. While some religions strictly prohibit alcohol consumption, viewing it as sinful or harmful to spiritual and physical well-being, others incorporate it into their rituals and ceremonies. Throughout history, alcohol has held significant roles in religious observances, from the use of sacramental wine in Christian sacraments to the offering and moderate drinking of omiki (sacramental sake) in Shinto purification rituals.

Eighteen local authorities have applied to delay their elections until 2026 amid proposals for major reorganisation. Ed Davey calls for Britain to re-join the European Union Customs Union. MP Joe Morris raises the topic of "Holly's Law" in Prime Minister's Questions. 16 January – Keir Starmer signs a 100-year treaty with Ukraine in Kyiv. Home Secretary Yvette Cooper announces plans for a nationwide review of grooming gangs including five government-backed local inquiries. Kemi Badenoch criticises her predecessors for mishandling Brexit. Downing Street clears Emma Reynolds to be City Minister despite her past work as a lobbyist. MP Mike Amesbury admits to assault at Chester Magistrates' Court. The White House announces that Ian Paisley Jr will attend the second inauguration of Donald Trump. 17 January – The Greater London Authority is to investigate Mayor of London Sadiq Khan for his acceptance of tickets to a Taylor Swift concert. Westminster's Strangers' Bar is to close for a safety and security review after a report that a woman had her drink spiked. The Liberal Democrats urge the UK government to release analysis of the potential impact of the US imposing trade tariffs on the UK economy after US President-elect Donald Trump threatened to impose tariffs of up to 20% on global imports.

The Port of Singapore, managed by port operators PSA International and Jurong Port, was the world's second-busiest port in 2019 in terms of shipping tonnage handled, at 2.85 billion gross tons (GT), and in terms of containerised traffic, at 37.2 million twenty-foot equivalent units (TEUs). It is also the world's second-busiest, behind Shanghai, in terms of cargo tonnage with 626 million tons handled. In addition, the port is the world's busiest for transshipment traffic and the world's biggest ship refuelling centre.

Sources: en.wikipedia.org

Frequently asked questions

What is Selank?

Selank is a synthetic seven-amino-acid peptide modeled on tuftsin, a fragment of the immunoglobulin G heavy chain. It was designed in Russia to combine anxiolytic and immunomodulatory properties in one molecule.

How does it relate to tuftsin?

The first four residues of Selank reproduce the tuftsin sequence Thr-Lys-Pro-Arg. A Pro-Gly-Pro extension at the C-terminus was added to slow enzymatic breakdown and extend residence time.

Is Selank an approved medicine?

It holds marketing authorization in Russia, where nasal drop formulations are sold. No equivalent approval exists in the European Union, the United States, or most other countries.

What is the primary sequence of Selank?

The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter code. It combines the tetrapeptide tuftsin with a carboxyl-terminal Pro-Gly-Pro extension. This full sequence identifies the molecule more precisely than the research name.

Network